Imbruvica approved for previously treated patients with Chronic Lymphocytic Leukemia, available at Biologics

14-02-2014 Business Wire HealthComments (0)


Biologics, a limited distribution network partner for IMBRUVICA (ibrutinib), is pleased to announce the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA (ibrutinib) capsules as a single, oral agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. The drug was originally approved on November 13, 2013 for the treatment of patients with mantle cell lymphoma (MCL) who have received at lea

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top